Clinical Trial Update: Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab with concurrent radiation in previously treated carcinoma of unknown primary was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma of Unknown Primary

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Carcinoma, Unspecified Site | Phase 2 | Status: TERMINATED | Results posted: 2022-12-23